Pradax (dabigatran etexilate) to compete with warfarin and heparins

Canada is leading the pack in North America by approving Pradax (dabigatran etexilate) to compete with warfarin and heparins.

It's the first new ORAL anticoagulant approved in Canada in over 40 years. It won't be approved in the U.S. for a year or more.

Pradax is a direct thrombin inhibitor.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter Canada includes:

  • 12 issues every year, with brief articles about new meds and hot topics
  • 300+ CE courses, including the popular CE-in-the-Letter
  • Quick reference drug comparison charts
  • Access to the entire archive

Already a subscriber? Log in

Volume pricing available. Get quote